Comparison · NCT01682759-sae
Omarigliptin vs Glimepiride: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Omarigliptin vs Glimepiride: serious adverse events. Trial comparisons, record NCT01682759-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01682759-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.064 | 0.0434 | 0.0935 | wilson | |
| Risk in group 2 | 0.048 | 0.0306 | 0.0746 | wilson | |
| Risk difference, group 1 minus group 2 | 0.016 | -0.0176 | 0.0502 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.33 | 0.736 | 2.42 | log | |
| Odds ratio, group 1 over group 2 | 1.36 | 0.723 | 2.54 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Omarigliptin than on Glimepiride | 62.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Omarigliptin | Participants will receive omarigliptin, 25 mg once weekly and placebo matching glimepiride once daily for up to 54 weeks. | 24 | 375 | EG000 |
| Group 2 | Glimepiride | Participants will receive glimepiride titrated to a maximum of 6 mg, once daily, and placebo to omarigliptin, once weekly for up to 54 weeks. | 18 | 375 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Up to Week 57
Source ClinicalTrials.gov
Trial
- Title
- A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)
- NCT number
- NCT01682759
- Phases
- PHASE3
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Omarigliptin, Placebo to Omarigliptin, Glimepiride, Glimepiride Placebo, Metformin, Insulin Glargine
- Lead sponsor
- Merck Sharp & Dohme LLC
- Results first posted
- 2016-02-05
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01682759?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01682759-sae